Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms, Plasma Cell × Thalidomide × Clear all

Phase

Phase 2 18 Phase 3 9 Phase NA 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 4 Carcinoma, Hepatocellular 2 Prostatic Neoplasms 1 Plasmacytoma 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Immunoglobulin Light-chain Amyloidosis 1 Carcinoma, Renal Cell 1 Amyloidosis 1

Interventions

Melphalan 13 Dexamethasone 11 Bortezomib 8 Peripheral Blood Stem Cell Transplantation 7 Lenalidomide 6 Calcium Dobesilate 6 fludarabine phosphate 5 pomalidomide 4 carfilzomib 4 Prednisone 4 Busulfan 4 liposomal doxorubicin 3 fludarabine 3 Tacrolimus 3 Methotrexate 3 Arsenic Trioxide 3 samarium Sm-153 lexidronam 2 holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 2 daratumumab 2 Whole-Body Irradiation 2 Radiotherapy 2 Granulocyte Colony-Stimulating Factor 2 Filgrastim 2 Bendamustine Hydrochloride 2 Ascorbic Acid 2 selinexor 1 sargramostim 1 ruxolitinib 1 resiquimod 1 poly ICLC 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00406978 2016-05-10

MPTD

University of Turin, Italy

Phase 1/2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡